These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 20368393)

  • 21. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
    Kashiwagi S; Watanabe A; Ikematsu H; Awamura S; Okamoto T; Uemori M; Ishida K
    J Infect Chemother; 2013 Aug; 19(4):740-9. PubMed ID: 23732307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
    Ikematsu H; Kawai N; Kashiwagi S
    J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
    Kawai N; Ikematsu H; Kawashima T; Maeda T; Ukai H; Hirotsu N; Iwaki N; Kashiwagi S
    Influenza Other Respir Viruses; 2013 May; 7(3):448-55. PubMed ID: 22897904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Oba K; Togashi T; Morita K; Inagawa A; Okamura A; Yamazaki S; Shida S; Konno M; Kawamura N; Ishizaka A; Takada K; Tsubakihara K; Nagano N; Shibata M; Furuyama H; Matsuzono Y; Koike A; Murashita M; Hatae Y; Arioka H; Yamanaka T; Watanabe T; Tabata Y; Kumita Y; Hazama K; Akutsu Y; Aoyagi H; Tobise C; Azuma K; Yasoshima K; Sawada Y; Uetsuji K; Tsuchida A; Tsuchiyama A; Yasuda K; Odagawa Y; Yoshioka M
    J Infect Chemother; 2018 Jun; 24(6):449-457. PubMed ID: 29487035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
    Heneghan CJ; Onakpoya I; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Mahtani KR; Nunan D; Howick J; Jefferson T
    Health Technol Assess; 2016 May; 20(42):1-242. PubMed ID: 27246259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
    Nakano T; Ishiwada N; Sumitani T; Uemori M; Isobe K;
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
    Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
    Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
    Kubo S; Kakuta M; Yamashita M
    Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
    Toyama K; Furuie H; Ishizuka H
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    J Infect Chemother; 2013 Apr; 19(2):223-32. PubMed ID: 23085742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
    Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
    Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
    Hirotsu N; Saisho Y; Hasegawa T
    Influenza Other Respir Viruses; 2019 Mar; 13(2):123-132. PubMed ID: 29989680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.